drug_type
RELEVANT_DRUG
intervention_type
Drug (antibody-drug conjugate)
drug_description
A humanized anti-TROP2 IgG1 antibody-drug conjugate that, after binding TROP2 on tumor cells and internalization, releases a membrane-permeable topoisomerase I inhibitor (DXd) via a cleavable linker to induce DNA damage, replication stress, and tumor cell death with a bystander effect.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Datopotamab Deruxtecan
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti-TROP2 IgG1 antibody-drug conjugate; after binding TROP2 and internalization, a cleavable linker releases the DXd topoisomerase I inhibitor payload, inducing DNA damage and replication stress to kill tumor cells, with a membrane-permeable bystander effect.
drug_name
Datopotamab deruxtecan (Dato-DXd; DS-1062a)
nct_id_drug_ref
NCT06176261